United Therapeutics CorporationUTHRNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +22.89% | +19.72% | +17.22% | +11.71% | +6.76% |
| Gross Profit Growth | +23.46% | +21.39% | +16.05% | +11.60% | +4.93% |
| EBITDA Growth | +22.77% | +30.81% | -10.33% | +29.00% | +10.79% |
| Operating Income Growth | +4.92% | +37.52% | +7.44% | +13.94% | +13.23% |
| Net Income Growth | +15.51% | +38.78% | +5.09% | +11.29% | +9.58% |
| EPS Growth | +21.37% | +45.89% | +10.12% | +9.58% | +11.54% |
| EPS Diluted Growth | +18.77% | +41.97% | +7.46% | +9.57% | +12.05% |
| Weighted Average Shares Growth | -4.90% | -3.83% | -4.47% | +1.58% | -1.79% |
| Weighted Average Shares Diluted Growth | -2.62% | -2.21% | -2.21% | +1.68% | -2.27% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +8.95% | +126.41% | +22.50% | -17.44% | +49.02% |
| Free Cash Flow Growth | +7.20% | +253.47% | +14.19% | -30.79% | +16.93% |
| Receivables Growth | +32.17% | +0.14% | +4.78% | +30.48% | -12.90% |
| Inventory Growth | +40.65% | +41.23% | +37.60% | +23.96% | +20.31% |
| Asset Growth | +1.42% | +2.75% | +19.22% | +17.62% | +3.20% |
| Book Value per Share Growth | +12.31% | +11.96% | +33.49% | +23.96% | +9.99% |
| Debt Growth | -50.00% | -57.14% | -66.67% | -100.00% | -100.00% |
| R&D Expense Growth | +22.20% | -11.62% | +43.13% | -4.01% | +23.19% |
| SG&A Expenses Growth | +71.79% | +22.92% | +17.80% | +7.43% | -16.70% |